About 1.90 million shares traded. Amicus Therapeutics, Inc. has a 12 month low of $6.41 and a 12 month high of $17.40.
Novavax, Inc. (NASDAQ:NVAX) recent gain occurred on low volume with 4.61 million contracts changing hands on 09-Mar-18.
Bryn Mawr Trust Company increased its stake in Cirrus Logic (CRUS) by 13.91% based on its latest 2017Q3 regulatory filing with the SEC.
Currently Amicus Therapeutics (NASDAQ:FOLD)'s shares owned by insiders are 0.8%, whereas shares owned by institutional owners are 0%. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.11). Evercore Wealth Management Llc who had been investing in Medtronic Plc for a number of months, seems to be bullish on the $112.70B market cap company. Crowley John F had sold 71,735 shares worth $1.06M on Tuesday, October 17. General Electric Company (NYSE:GE) has declined 4.46% since March 10, 2017 and is downtrending. Strs Ohio bought a new position in Amicus Therapeutics in the 3rd quarter valued at $102,000. Hudson Bay Management Limited Partnership has 0.04% invested in Amicus Therapeutics, Inc.
Since October 12, 2017, it had 2 insider purchases, and 17 insider sales for $8.39 million activity. 32,500 shares were sold by Campbell Bradley L, worth $517,371 on Monday, January 22. Another trade for 9,366 shares valued at $140,490 was made by RAAB MICHAEL on Tuesday, January 2. It is positive, as 73 investors sold MDT shares while 392 reduced holdings.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Shares for $1.37M were bought by PERCEPTIVE ADVISORS LLC. Do Hung sold $715,360 worth of stock. Amicus Therapeutics, Inc.is given 3 buy-equivalent recommendations, 0 sells and 1 holds. Therefore 89% are positive.
On average, analysts expect that Amicus Therapeutics will report full-year sales of $16.78 million for the current year, with estimates ranging from $80.96 million to $85.74 million. (NASDAQ:FOLD) on Wednesday, September 16 to "Neutral" rating. BMO Capital Markets has "Hold" rating and $20800 target. The stock has "Buy" rating by Cowen & Co on Sunday, August 13. The rating was maintained by Robert W. Baird with "Outperform" on Wednesday, July 12. On Monday, August 31 the stock rating was maintained by Leerink Swann with "Buy". Finally, Cowen reissued a "buy" rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 10th.
According to Zacks, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases". The firm earned "Buy" rating on Tuesday, August 18 by Zacks. Cowen & Co maintained General Electric Company (NYSE:GE) rating on Thursday, October 19. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold FOLD shares while 32 reduced holdings.
Artal Group Sa, which manages about $5.81 billion US Long portfolio, decreased its stake in Morgan Stanley (Call) (NYSE:MS) by 200,000 shares to 300,000 shares, valued at $14.45 million in 2017Q3, according to the filing. Numeric Investors Ltd Liability Com accumulated 648,798 shares or 0.39% of the stock. Nicholas Invest Partners Limited Partnership stated it has 134,388 shares or 0.14% of all its holdings. Voya Investment Llc owns 76,119 shares or 0% of their USA portfolio. Amicus Therapeutics earned a news sentiment score of 0.17 on Accern's scale.
Shares of Amicus Therapeutics (FOLD) opened at $14.91 on Thursday. $147,191 worth of Amicus Therapeutics, Inc. State Bank Of America De, a North Carolina-based fund reported 529,913 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 7,138 shares. Blackrock Incorporated stated it has 0.01% in Amicus Therapeutics, Inc. Green Square Capital Ltd Limited Liability Company holds 26,726 shares. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD). Bnp Paribas Arbitrage has invested 0% in Amicus Therapeutics, Inc. The insider KING CHRISTINE sold 5,000 shares worth $272,544. Groves Jeffrey Lynn sold $2.53M worth of stock.
Investors sentiment increased to 1.02 in 2017 Q3. Its up 0.22, from 0.9 in 2017Q2. (NASDAQ:FOLD) was sold by Barth Jay. Tower Limited Liability (Trc) has invested 0.02% in Cirrus Logic, Inc. (NASDAQ:CRUS). Public Employees Retirement System Of Ohio reported 0.01% stake. (NASDAQ:CRUS). 61 are held by First Personal Svcs. Fortaleza Asset Mgmt accumulated 7,215 shares. Liberty Management has invested 0.36% of its portfolio in General Electric Company (NYSE:GE). (NASDAQ:CRUS). Massachusetts-based State Street Corp has invested 0.01% in Cirrus Logic, Inc. (NASDAQ:CRUS). Natixis owns 8,989 shares. New Amsterdam Ltd Liability Co New York reported 1.9% of its portfolio in Cirrus Logic, Inc. Following the completion of the transaction, the chief financial officer now owns 105,121 shares in the company, valued at approximately $1,547,381.12. It also reduced its holding in Boeing Company (NYSE:BA) by 216,743 shares in the quarter, leaving it with 2,165 shares, and cut its stake in Norfolk Southern Corp (NYSE:NSC).
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.